Your browser doesn't support javascript.
loading
Progression to pancreatic ductal adenocarcinoma from pancreatic intraepithelial neoplasia: Results of a simulation model.
Peters, Mary Linton B; Eckel, Andrew; Mueller, Peter P; Tramontano, Angela C; Weaver, Davis T; Lietz, Anna; Hur, Chin; Kong, Chung Yin; Pandharipande, Pari V.
Afiliação
  • Peters MLB; Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, USA; Institute for Technology Assessment, Massachusetts General Hospital, USA. Electronic address: mbpeters@bidmc.harvard.edu.
  • Eckel A; Institute for Technology Assessment, Massachusetts General Hospital, USA.
  • Mueller PP; Institute for Technology Assessment, Massachusetts General Hospital, USA.
  • Tramontano AC; Institute for Technology Assessment, Massachusetts General Hospital, USA.
  • Weaver DT; Institute for Technology Assessment, Massachusetts General Hospital, USA.
  • Lietz A; Institute for Technology Assessment, Massachusetts General Hospital, USA.
  • Hur C; Institute for Technology Assessment, Massachusetts General Hospital, USA.
  • Kong CY; Institute for Technology Assessment, Massachusetts General Hospital, USA.
  • Pandharipande PV; Institute for Technology Assessment, Massachusetts General Hospital, USA.
Pancreatology ; 18(8): 928-934, 2018 Dec.
Article em En | MEDLINE | ID: mdl-30143405
ABSTRACT

OBJECTIVES:

To gain insight into the natural history and carcinogenesis pathway of Pancreatic Intraepithelial Neoplasia (PanIN) lesions by building a calibrated simulation model of PanIN progression to pancreatic ductal adenocarcinoma (PDAC)

METHODS:

We revised a previously validated simulation model of solid PDAC, calibrating the model to fit data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program and published literature on PanIN prevalence by age. We estimated the likelihood of progression from PanIN states (1, 2, and 3) to PDAC and the time between PanIN onset and PDAC (dwell time). We evaluated a hypothetical intervention to test for and treat PanIN 3 lesions to estimate the potential benefits from PanIN detection.

RESULTS:

We estimated the lifetime probability of progressing from PanIN 1 to PDAC to be 1.5% (men), 1.3% (women). Progression from PanIN 1 to PDAC took 33.6 years and 35.3 years, respectively, and from PanIN 3 to PDAC took 11.3 years and 12.3 years. A hypothetical test for PanIN 3 detection and treatment could provide a maximum, average life expectancy gain of 40 days.

CONCLUSIONS:

Our modeling analysis estimates PanINs have a relatively indolent course to PDAC, supporting the feasibility of potential future early detection strategies.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma in Situ / Adenocarcinoma / Carcinoma Ductal Pancreático Tipo de estudo: Incidence_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Aspecto: Patient_preference Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Pancreatology Assunto da revista: ENDOCRINOLOGIA / GASTROENTEROLOGIA Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma in Situ / Adenocarcinoma / Carcinoma Ductal Pancreático Tipo de estudo: Incidence_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Aspecto: Patient_preference Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Pancreatology Assunto da revista: ENDOCRINOLOGIA / GASTROENTEROLOGIA Ano de publicação: 2018 Tipo de documento: Article